The Nuffield Department of Clinical Medicine of University of Oxford is developing a rectal formulation of a cephalosporin antibiotic used to treat neonatal sepsis. Rectal administration of antibiotics is a safe and effective method for infants and children. The Department is hoping to develop a stable rectal formula of the antibiotic through a Phase 1 study in humans, Phase 2 trial in infants, and a Phase 3 trial to determine its effect on neonatal mortality. The proposed antibiotic can be administered by community-based interventions and potentially save millions of infants. The Department is currently seeking funding for two years in order to begin with pharmaceutical research and carry out preliminary animal studies.